ReviewAdvances in experimental medicine and biology2021
Lung Extracellular Matrix as a Platform for Lung Organ Bioengineering: Design and Development of Tissue Engineered Lung.
Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 3D bioprinting of the airways and lungs for applications in tissue engineering and in vitro models.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since lung tissue is not able to be reconstructed after substantial injury, lung transplantation often is the only alternative for treatment. Antibiotic-resistant organisms that remain in donor lungs causing infection in the immunosuppressed recipient are among the complications following transplantation. Development of strategies for whole lung regeneration is a pleasing choice particularly in patients with end-stage lung diseases. Reconstruction of lung tissue in vitro for transplantation received increased attention which could deal with the shortage of donor organs. Recent advancements in the field of tissue engineering and regenerative medicine have paved the road for beneficial alternative therapies. Our group has extensive experience with regard to the structure of the lung tissue, which makes us to our decision to continue with the preparation of lung, with the aim of developing a new ECM scaffold. Herein, we aim to review the state-of-art and the tissue engineering and regenerative medicine technology highlighting the major achievements toward the production of a bioengineered lung obtained decellularization and recellularization techniques. We have strong hopes that recent developments in the engineering of lung will lead to similar breakthroughs in the engineering of distal lung components in the future.
Indexed as
Identifiers
34582012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.